MedPath

Naturalistic Monitoring and Treatment of Chronic Insomnia

Not Applicable
Completed
Conditions
Chronic Insomnia
Interventions
Device: SleepScore Max coaching feature
Behavioral: Online CBTi
Registration Number
NCT04013321
Lead Sponsor
Washington State University
Brief Summary

90 individuals with chronic insomniacs and 30 healthy normal sleepers will have their sleep monitored by the SleepScore Max for 10 weeks. Individuals with chronic insomnia will be randomized into one of three groups (30 subjects in each): a test intervention group, a passive control group, and an active control group. The purpose of the study is to examine if the SleepScore max provides a accurate measurement of sleep relative to a validated, wrist-worn sleep monitor and if a integrated coaching feature within the SleepScore Max facilitates improvement in sleep relative to other gold standard treatment methods.

Detailed Description

90 chronic insomniacs, carefully screened using the criteria of Chronic Insomnia Disorder according to the International Classification of Sleep Disorders 3 (ICSD-3), will be studied. Additionally, 30 healthy normal sleepers will be included as controls. The duration of study participation will be 10 weeks. All subjects will wear an actigraph during week 1 to record baseline sleep patterns, followed by 8 weeks of recording with the SleepScore Max. During week 10, the subjects will wear the actigraph again to measure post intervention sleep. The healthy subjects will be used as a control to test if the SleepScore Max can track sleep well as compared to actigraphy. The subjects with chronic insomnia will be randomized into one of three groups (30 subjects in each). One of these groups is the test intervention group, in which subjects will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device. The other two groups will serve as passive and active controls. The passive control group will track their sleep using the SleepScore Max device, but without any feedback or coaching. The active control group will also be tracking their sleep with the device, without feedback or coaching, but they will also undergo online CBTi which is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
112
Inclusion Criteria
  • Age 18-65
  • Physically and psychologically healthy (except for chronic insomnia for the insomnia participants) as assessed by questionnaires and history
  • No sleep disorders other than chronic insomnia (for insomnia participants only) as assessed by questionnaires and history
  • Has daily access to an iPhone
Exclusion Criteria
  • Non-English speaking

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Test intervention groupSleepScore Max coaching featureChronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
Active controlOnline CBTiChronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
Primary Outcome Measures
NameTimeMethod
Sleep Duration10 weeks

Quantify sleep duration using Actigraphy in:

* Passive control insomniacs vs healthy controls

* Insomnia groups

Secondary Outcome Measures
NameTimeMethod
Sleep latency10 weeks

Quantify sleep latency using actigraphy in:

* Passive control insomniacs vs healthy controls

* Insomnia groups

Intermittent wakefulness10 weeks

Quantify intermittent wakefulness using actigraphy in:

* Passive control insomniacs vs healthy controls

* Insomnia groups

Trial Locations

Locations (1)

Sleep and Performance Research Center

🇺🇸

Spokane, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath